Luxeptinib (CG-806) Targets FLT3 and Clusters of Kinases Operative in Acute Myeloid Leukemia

Luxeptinib (CG-806) simultaneously targets FLT3 and select other kinase pathways operative in myeloid malignancies. We investigated the range of kinases it inhibits, its cytotoxicity landscape ex vivo with acute myeloid leukemia (AML) patient samples, and its efficacy in xenograft models. Luxeptinib...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Molecular cancer therapeutics 2022-07, Vol.21 (7), p.1125-1135
Hauptverfasser:	Rice, William G, Howell, Stephen B, Zhang, Hongying, Rastgoo, Nasrin, Local, Andrea, Kurtz, Stephen E, Lo, Pierrette, Bottomly, Daniel, Wilmot, Beth, McWeeney, Shannon K, Druker, Brian J, Tyner, Jeffrey W
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Dogs fms-Like Tyrosine Kinase 3 - genetics fms-Like Tyrosine Kinase 3 - metabolism Humans Leukemia, Myeloid, Acute - drug therapy Leukemia, Myeloid, Acute - genetics Leukemia, Myeloid, Acute - metabolism Mice Mutation Protein Kinase Inhibitors - pharmacology Protein Kinase Inhibitors - therapeutic use Signal Transduction
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!